Table 1.
Top Canonical Pathways Regulated by CL316,243 in WT BAT and Their Ranking in ERRαγAd−/− BAT
| Canonical Pathway | WT Mice |
ERRαγAd−/− Mice |
||||||
|---|---|---|---|---|---|---|---|---|
| Rank | Downregulated | Upregulated | -log(p Value) | Rank | Downregulated | Upregulated | -log(p Value) | |
| Mitochondrial dysfunction | 1 | 8/142 (6%) | 79/142 (56%) | 9.29E+00 | NA | |||
| Oxidative phosphorylation | 2 | 2/85 (2%) | 62/85 (73%) | 8.92E+00 | NA | |||
| TCA cycle II (eukaryotic) | 3 | 0/19 (0%) | 17/19 (89%) | 7.22E+00 | 27 | 0/19 (0%) | 13/19 (68%) | 2.03E+00 |
| Fatty acid β-oxidation I | 4 | 0/26 (0%) | 16/26 (62%) | 6.80E+00 | 1 | 0/26 (0%) | 21/26 (81%) | 8.28E+00 |
| Glutaryl-CoA degradation | 5 | 1/15 (7%) | 11/15 (73%) | 6.66E+00 | 39 | 1/15 (7%) | 11/15 (73%) | 1.72E+00 |
| Tryptophan degradation III (eukaryotic) | 6 | 1/15 (7%) | 11/15 (73%) | 6.66E+00 | 40 | 1/15 (7%) | 11/15 (73%) | 1.72E+00 |
| Valine degradation I | 7 | 0/17 (0%) | 13/17 (76%) | 5.81E+00 | 8 | 0/17 (0%) | 15/17 (88%) | 4.01E+00 |
| Acetyl-CoA biosynthesis I (pyruvate dehydrogenase complex) | 8 | 0/5 (0%) | 5/5 (100%) | 4.34E+00 | 215 | 0/5 (0%) | 3/5 (60%) | 5.08E-01 |
| Allograft rejection signaling | 9 | 11/19 (58%) | 0/19 (0%) | 4.23E+00 | 5 | 12/19 (63%) | 0/19 (0%) | 4.60E+00 |
| LXR/RXR activation | 10 | 13/64 (20%) | 16/64 (25%) | 4.20E+00 | 15 | 17/64 (27%) | 8/64 (13%) | 2.76E+00 |
| Autoimmune thyroid disease signaling | 11 | 9/13 (69%) | 0/13 (0%) | 4.12E+00 | 30 | 8/13 (62%) | 1/13 (8%) | 1.95E+00 |
| Isoleucine degradation I | 12 | 1/13 (8%) | 9/13 (69%) | 4.12E+00 | 69 | 1/13 (8%) | 11/13 (85%) | 1.21E+00 |
| Complement system | 13 | 13/23 (57%) | 1/23 (4%) | 4.11E+00 | 3 | 14/23 (61%) | 2/23 (9%) | 6.83E+00 |
| Antigen presentation pathway | 14 | 11/24 (46%) | 1/24 (4%) | 3.90E+00 | 4 | 17/24 (71%) | 1/24 (4%) | 5.58E+00 |
| Gluconeogenesis I | 15 | 2/17 (12%) | 10/17 (59%) | 3.88E+00 | 104 | 6/17 (35%) | 3/17 (18%) | 9.28E-01 |